Beam Therapeutics Stock Forecast, Price & News

Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BEAM stock has increased by 78.3% and is now trading at $37.89.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beam Therapeutics.

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Beam Therapeutics.

Beam Therapeutics Inc (NASDAQ:BEAM) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.13. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.
View Beam Therapeutics' earnings history.

2 analysts have issued 12-month price targets for Beam Therapeutics' stock. Their forecasts range from $33.00 to $33.00. On average, they anticipate Beam Therapeutics' share price to reach $33.00 in the next year. This suggests that the stock has a possible downside of 12.9%.
View analysts' price targets for Beam Therapeutics.

Some companies that are related to Beam Therapeutics include Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Twist Bioscience (TWST) and Ablynx (ABLYF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), InVitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BEAM stock can currently be purchased for approximately $37.89.

Beam Therapeutics has a market capitalization of $1.96 billion and generates $20,000.00 in revenue each year. The company earns $-78,330,000.00 in net income (profit) each year or ($14.05) on an earnings per share basis.

The official website for Beam Therapeutics is www.beamtx.com.

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-327-8775 or via email at [email protected]